Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Tag: tezepelumab Tezspire
All
Latest
Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
Asthma Biologics Not Tied to Increased Respiratory Infections
Biologics including Dupilumab and anti-IL-5 agents were associated with a lower probability of pneumonia within the study.
Read More
Tezspire Approved in EU for CRSwNP
The European Commission approved Tezspire (tezepelumab) as an add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
FDA Approves Tezspire for CRSwNP
Tezspire (tezepelumab-ekko) is now FDA-approved for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older.
Read More
EU Panel Recommends Tezspire for Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Tezepelumab Reduced, Eliminated OCS Use in Severe Asthma Patients
Treatment with tezepelumab (Tezspire) can substantially reduce or eliminate oral corticosteroid (OCS) use in adults with OCS-dependent severe asthma, according to new Phase 3 WAYFINDER results presented at ATS 2025.
Read More
Tezspire Significantly Reduced Nasal Congestion, Polyp Size in CRwNP Patients
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More
Positive Data for Tezspire in COPD Patients
New data presented at ATS 2024 show the potential of Tezspire to play a role in the future treatment of COPD.
Read More
Severe Asthma Management
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read More
Tezepelumab Improved Severe Asthma in Half of Patients
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
Read More
Study: Efficacy of Tezspire in Severe Asthma Patients
Tezspire (tezepelumab) demonstrated reductions in the annualized asthma exacerbation rate across biomarker subgroups of patients with severe asthma.
Read More
FDA OKs Tezspire for Severe Asthma
The FDA approved AstraZeneca and Amgen’s medication, Tezspire, to treat severe asthma for patients aged 12 years and older.
Read More
Tezepelumab Reduced Exacerbation Rates in severe Asthma 77%
A Phase 3 trial of AstraZeneca/Amgen’s Tezepelumab found the drug had a clinically meaningful 77% reduction in annualized asthma exacerbation rates in patients with severe asthma.
Read More